Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

Peter J. Ruane, M.D., Inc.40 enrolled

Overview

This study is evaluating the safety and efficacy of a 12 week treatment LDV/SOF FDC in patients with Chronic GT1 or GT4 HCV infection and autoimmune disease

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Hepatitis C

Interventions

LDV/SOF FDCDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic GT1 or GT4 HCV Infection * Diagnosed with autoimmune disease (rheumatoid arthritis, psoriatic arthritis, lupus, etc.) and is currently receiving treatment for the condition. Exclusion Criteria: * Infection with HIV or HBV

Locations (1)

Peter J. Ruane, MD, Inc.

Los Angeles, California, United States

Outcomes

Primary Outcomes

SVR12 (Sustained Virologic Response)

Time frame: Sustained Virologic Response 12 Weeks after Treatment Completion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.